The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from baseline in self-reported anhedonia scores on the Dimensional Anhedonia Rating Scale (DARS).
Timeframe: One week post-dosing